Shingles Clinical Trial
Official title:
A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors
Verified date | April 2018 |
Source | Louis Stokes VA Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates if the shingles vaccine works in those persons that receive it before they receive chemotherapy for solid organ tumors. Half of the participants will receive the ZOSTAVAX shingle vaccine and half of the participants will not received anything.
Status | Active, not recruiting |
Enrollment | 22 |
Est. completion date | May 1, 2018 |
Est. primary completion date | May 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - Solid organ tumor patients that have at least 14 days between entry into the study with ZOSTAVAX vaccination and initial therapy for their malignancy that will include chemotherapy alone or surgery with subsequent chemotherapy plus or minus radiation therapy - A plan for chemotherapy that at the onset at least an anticipated stop date within 3-6 months of our sample collection phase of the study Exclusion Criteria: - Prior history of HZ or shingles vaccine - Systemic chemotherapy < 3 months prior to enrollment - Any history of hematologic malignancy, HIV/AIDS, hematopoietic stem cell transplant, or other cellular immunodeficiency state - Those receiving immunomodulating drugs at the time of vaccination such as prednisone methotrexate, azathioprine, mercaptopurine, or other biologics including TNF-alpha inhibitors - Widespread metastatic tumor with bone marrow involvement - Indefinite duration palliative chemotherapy subjects - Inability to communicate with the study staff or bring unable to consent for themselves - History of anaphylactic/anaphylactiod reaction to gelatin, neomycin, or other components of the vaccine |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Louis Stokes VA Medical Center | Duke University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Measuring the Efficacy of ZOSTAVAX in Chemotherapy Patients (Changes in ZOSTAVAX-specific IFN-gamma Spot Forming Units Will be Measured by ELISPOT) | To examine the cellular immunologic efficacy as measured by IFN-gamma assays of ZOSTAVAX given to individuals with solid organ tumors at least 14 days prior to initiation of chemotherapy or surgery and then chemotherapy. Changes in ZOSTAVAX-specific IFN-gamma spot forming units will be measured by ELISPOT. | 3 years | |
Primary | Measuring the Safety of ZOSTAVAX Given to Chemotherapy Patients (Vaccine Report Card (VRC) to Document Injection-site Adverse Experiences, Systemic Clinical Adverse Experiences (AEs), Concomitant Medications, and Oral Temperatures | To asses the safety of ZOSTAVAX given to subjects that will receive chemotherapy or surgery and then chemotherapy for solid organ tumor at least 14 days after vaccination. Safety and tolerability data will be collected for all subjects throughout the study. Each subject will be given a Vaccine Report Card (VRC) to document injection-site adverse experiences, systemic clinical adverse experiences (AEs), concomitant medications, and oral temperatures (only if feeling feverish) noted during the 14-day post-vaccination period. Participants will be asked to notify the study personnel immediately if any unexpected or serious adverse experience (SAE) occurs. At all study visits subjects will be asked about any unreported SAEs. All AEs and SAEs will be recorded on an AE/SAE case report form and relationship to study vaccine will be determined by the site investigator. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Completed |
NCT04540081 -
Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer
|
N/A | |
Completed |
NCT01527370 -
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
|
Phase 3 | |
Completed |
NCT00534248 -
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
|
Phase 3 | |
Completed |
NCT01262300 -
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents
|
Phase 1 | |
Completed |
NCT00576108 -
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00109122 -
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
|
Phase 2 | |
Completed |
NCT04047979 -
Systems Biology of Zoster Vaccine
|
Phase 2 | |
Active, not recruiting |
NCT05871541 -
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
|
Phase 1 | |
Completed |
NCT02114333 -
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
|
Phase 1 | |
Completed |
NCT00900783 -
A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
|
Phase 2 | |
Completed |
NCT01600079 -
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
|
||
Recruiting |
NCT05554068 -
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT06238726 -
Nudging Patients to Increase Shingles Vaccination
|
N/A | |
Completed |
NCT02704572 -
Optimal Timing of Zoster Vaccine After Zoster Illness
|
N/A | |
Completed |
NCT00300222 -
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
|
Phase 3 | |
Terminated |
NCT02412917 -
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
|
Phase 3 | |
Completed |
NCT00115310 -
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
|
Phase 3 |